References
- Baguley B. C., Falkenhaug E.-M. Plasma half-life of cytosine arabinoside in patients with leukemia—the effect of uridine. Eur. J. Cancer 1975; 11: 43
- Buchman V. M., Svet-Moldavsky G. J., Lichinitser M. K., Mkheidze D.M. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2-deoxycytidine and lethal doses of cytosine-arabinoside. Biomed 1977; 27: 179
- Børyum A. Separation of blood leukocytes, gran-ulocytes and lymphocytes. Antigens 1974; 4: 269
- Chabner B. A., Hande K. R., Drake J.C. Ara-C metabolism: implications for drug resistance and drug interactions:Bull. Cancer (Paris) 1979; 66: 89
- Chabner B. A., Johns D. G., Coleman C. N., Drake J. C., Evans W.H. Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J. clin. Invest 1974; 53: 922
- Cheng Y.-C., Domin B., Lee L.-S. Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitocondrial isozymes from blast cells of acute myelocytic leukemia patients. Biochem. Biophys. Acta 1977; 481: 481
- Chou T.-C., Arlin Z., Clarkson B. D., Philips F.R. Metabolism of 1-β-D-arabinofuranosykytosine in human leukemic cells. Cancer Res 1977; 37: 3561
- Cohen S.S. The mechanisms of the lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA). Cancer Res 1977; 40: 509
- Coleman C. N., Stoller R. C., Drake J. C., Chabner B.A. Deoxycytidine kinase: properties of enzyme from human leukemic granulocytes. Blood 1975; 46: 791
- Furth J. J., Cohen S.S. Inhibition of mammalian DNA polymerase by the 5-triphosphate of I-β-d-arabinofuranosylcytosine and the 5-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res 1968; 28: 2061
- Goldenthal E. I., Clookson K. M., Geil R. G., Wazeter F.X. Preclinical toxicologic evaluation of tetrahydrouridine (NSC-112097) in beagle dogs and rhesus monkeys. Cancer Chemother. Rep 1974; 5: 15
- Kreis W., Woodcock T. M., Gordon C. S., Krakoff I.H. Tetrahydrouridine physiologic disposition and effect upon deamination of cytosine arabinoside in man. Cancer Treat. Rep 1977; 61: 1347
- Lewis J. P., Linnian J. W., Marshall G. J., Pajak T. F., Bateman J.R. Randomized clinical trial of cytosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlympho-cytic acute leukemia. Cancer 1977; 39: 1387
- Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R.J. Protein measurement with folin phenol reagent. J. Biol. Chem 1951; 193: 256
- Mejer J., Nygaard P. Cytosine arabinoside phosphorylation and deamination in acute myelo-blastic leukemia cells. Leulc. Res 1978; 2: 127
- Momparler R.L. A model for the chemotherapy of acute leukemia with 1-β-D-arabinofuranosylcytosine. Cancer Res 1775, 1974; 34
- Mulder J. H., Harrap K.R. Cytosine arabinoside uptake by tumour cells. in vitro. Eur. J. Cancer 1975; 11: 373
- Van Prooijen H. C. Clinical pharmacology of cytosine arabinoside in acute myeloid leukemia. Clinical Pharmacology Anti-Neoplastic Drugs, J. M. Pinedo. North-Holland Biomedical Press, Elsevier. 1978; 177
- Roy-Burman P. Analogues of nucleic acid components. Springer, Berlin 1970
- Rustum Y. M. Metabolism and intracellular retention of 1-β-D-arabinofuranosylcytosine as predictors of response of animal turnours. Cancer Res 1978; 38: 543
- Steuart C. D., Burke P.J. Cytidine deaminase and development of resistance to arabinosyl cytosine. Nature New Biol 1971; 233: 109
- Tattersall M. H. N., Ganeshaguru K., Hoffbrand A.V. Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. Br. J. Haemar 1934; 27: 39